Jena (Germany), January 26, 2012 - On January 25, 2012, the Executive Board of Analytik Jena AG (Prime Standard: AJA, ISIN: DE0005213508) utilized the authorization granted by the Annual General Meeting on March 19, 2009 and resolved a cash capital increase from authorized capital. The Supervisory Board of Analytik Jena today approved the capital increase.

The share capital of the Company from the current figure of EUR 5,235,465.00 will be increased by partially utilizing the Authorized Capital by issuing 470,000 new no-par value bearer shares at a subscription price of EUR 10.480 per share with shareholders' subscription rights disapplied. The subscription price corresponds to the volume-weighted average price on the last five trading days (Xetra) less a discount of 3 %. The new shares will be fully subscribed by the Thüringer Industriebeteiligungs-GmbH & Co. KG (TIB), an investment fund managed by the bm-t beteilungsmanagement thüringen gmbh (bm-t), Erfurt. bm-t already holds an interest in Analytik Jena AG of 10.41 % and thus increases its stake to 17.79 %.

Analytik Jena AG intends to use the proceeds from the capital increase to finance the strategic development of the Company.

Analytik Jena has commissioned IKB Deutsche Industriebank AG to manage the transaction.

Contact:
Dana Schmidt
Analytik Jena AG
Konrad-Zuse-Strasse 1
07745 Jena | Germany
Phone: +49 (0) 36 41 77 92 81
E-mail: ir@analytik-jena.com

Jena (Germany), November 21, 2011 — Analytik Jena AG (Frankfurt DE0005213508, Prime Standard: AJA) achieved a sales growth of 7.6 % and an increase in the operating earnings of 59.3 % in the past financial year 2010/2011. The Company generated total sales for the Group of EUR 86.3 m (previous year: EUR 80.2 m) and an operating result (EBIT) of EUR 5.0 m (previous year: EUR 3.1 m).

The growth rates in sales and earnings were generated in both core business units Analytical Instrumentation and Life Science. The pure organic growth especially resulted from increasing foreign sales. The Company particularly participated from a disproportional growth in the Asian countries, where business increased by 20.4 %.

In the operating business Analytik Jena AG showed again a considerable increase compared to the previous year. The Group closed the last full financial year 2010/11 with earnings before interest, taxes, depreciation, and amortization (EBITDA) amounting to EUR 8.8 m (previous year: EUR 6.7 m) which corresponds to an increase by 31.0 %. The EBITDA margin amounts to 10.2 % (previous year: 8.4 %). The operating profit (EBIT) amounts to EUR 5.0 m (previous year: EUR 3.1 m) and therewith increased by 59.3 % compared to the previous year. The EBIT margin improved to 5.8 % in comparison to 3.9 % in the previous year.

On November 16, 2011, the tax audit of AJZ Engineering GmbH conducted by Gera Tax Office was consensually closed with an agreement. Due to the profit and loss transfer agreement that existed between AJZ Engineering and the parent company, Analytik Jena is faced with tax expenses. Extraordinary expenses totaling EUR 1.2 m arise for the 2003 to 2007 financial years. Tax arrears payment, that also includes effects of EUR 1.0 m for subsequent years, was completely booked in the past financial year and has a negatively impact on the EBT (interest expense) and the Earnings per Share (EPS). The investigations into AJZ Engineering have already been closed at the end of September against payment of an amount of EUR 300 thousand.

Contact:
Dana Schmidt
Analytik Jena AG
Konrad-Zuse-Strasse 1
07745 Jena/Germany
Tel. +49 (0) 36 41  77-92 81
Email: ir@analytik-jena.com

Jena (Germany), August 4, 2011 — After an agreement could be achieved in the tax audit of AJZ Engineering GmbH conducted by Gera Tax Office for the 2003 to 2007 financial years at the beginning of July, an agreement has also been reached with the public prosecution authority in Erfurt. This was announced today by Analytik Jena AG (Prime Standard: AJA, ISIN: DE0005213508), the holder of a 49.0% stake in AJZ Engineering GmbH.

The results of the tax audit of AJZ Engineering carried out by Gera tax office include an off-balance sheet addition of expenses leading to a tax arrears payment. The tax office is expected to submit its final audit report in October. There is no longer any accusation of possible tax evasion. Due to the profit and loss transfer agreement that existed between AJZ Engineering and the parent group Analytik Jena at the time of the audit, Analytik Jena AG will face extraordinary expenses totaling EUR 1.2 million. The adjustment of the balance sheet effects the preceding period and will not impact earnings for the current financial year.

With regard to investigations by Erfurt public prosecution authority into former and present members of management and employees of AJZ Engineering, an agreement was reached with the public prosecution authority on abandoning the proceedings. The outcome will mean discontinuation of the proceedings against both the suspects and AJZ Engineering upon fulfillment of certain requirements. We expect the proceedings to be officially closed at the end of the financial year.

Contact:
Dana Schmidt
Analytik Jena AG
Konrad-Zuse-Strasse 1
07745 Jena | Germany
Phone: +49 (0) 36 41  77-92 81
E-mail: ir@analytik-jena.com

Jena, November 22, 2010 — Analytik Jena AG (Frankfurt DE0005213508, Prime Standard: AJA) achieved sales of EUR 80.2 m in the 2009/2010 financial year (previous year: EUR 71.2 m) and in doing so once again exceeded the record sales of the previous year by 12.8%. The manufacturer of analytical, bioanalytical and optical systems and molecular diagnostic reagents continued to post above-average growth in the Life Science segment in particular and stable sales development in the core business of Analytical Instrumentation.

In terms of operating results Analytik Jena fell short of the previous year’s performance. The Group recorded EBIT of EUR 3.1 m in the financial year just ended (previous year: EUR 6.3 m), equivalent to a year-on-year decline of about 50.0%. Several one-off effects of in total more than EUR 2.0 m are included in the results such as the winding-up of CyBio Japan and higher costs for establishing a sales network for the Life Science segment in important Asian growth markets such as Japan and China. Further negative impact on earnings came from the gross margin, that is stagnant despite the strong US-Dollar, partially from capacity related factors with view to the continued weak business development in Optics, from high pricing pressure in all three business units as well as from ongoing investigations at the minority holding AJZ Engineering GmbH.

Earnings per share in the past financial year amount to EUR 0.34. (previous year: EUR 0.11). It should be noted here, that the previous year`s financial statements had to be adjusted as a result of the tax audit for 2003 to 2007 and a reclassification of currency translation. Accordingly earnings per share in the past financial year changed to EUR 0.11 (previously: EUR 0.51 EUR).

Based on the good results of the past few years, the Company will propose to the Supervisory Board that a dividend payment of EUR 0.15 per share be included in the agenda for the Annual General Meeting to be held on April 19, 2011.

The figures given in the announcement are preliminary figures. The final results for the 2009/2010 financial year (as at September 30) will be announced by the Group on December 16, 2010.

Contact:
Dana Schmidt
Analytik Jena AG
Konrad-Zuse-Strasse 1
07745 Jena | Germany
Phone: +49 (0) 36 41  77-92 81
E-mail: ir@analytik-jena.com

Jena, July 28, 2010 — Analytik Jena AG (Frankfurt DE0005213508, Prime Standard: AJA) today announced its preliminary sales and earnings figures for the first nine months of the current 2009/2010 financial year. The Thuringia-based provider of analytical instrumentation technology generated an operating result (EBIT) of EUR 3.2 m on the back of sales of EUR 59.6 m. Earnings per share amounted to EUR 0.47.

Based on the current course of business, the Company expects to record EBIT of around EUR 5.0 m and earnings per share of around EUR 0.60 for the financial year as a whole, down on its initial forecasts.

This adjustment is due to the sustained difficult development in the Optics segment, which has not enjoyed the recovery that was expected. The Company also reported non-recurring effects from the closure of CyBio Japan in the past quarter, as well as a sharp increase in costs for the establishment of a uniform international sales structure in the Life Science sector.

The Company still expects to achieve record sales of around EUR 80.0 m and intends to recommend the distribution of a dividend to the Supervisory Board at its meeting in December 2010 to adopt the annual financial statements.

This information is based on preliminary key financial figures. The complete figures for the first nine months of the 2009/2010 financial year will be announced on August 12, 2010.

Contact:
Dana Schmidt
Analytik Jena AG
Konrad-Zuse-Strasse 1
07745 Jena | Germany
Phone: +49 (0) 36 41  77-92 81
E-mail: ir@analytik-jena.com